Larazotide
Larazotide is a peptide, indexed here under Tissue repair peptides.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Tissue repair peptides |
| CAS registry number | 258818-34-7[1] |
| PubChem CID | 9810532[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C32H55N9O10[1] |
| Molecular weight | 725.8 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Larazotide, reported in the literature as larazotide acetate and by the code AT-1001, is an octapeptide studied as a regulator of epithelial tight junctions. Two 2012 Peptides papers report that it regulates tight junctions in vitro and in vivo and promotes tight junction assembly in epithelial cells, and a 2021 American Journal of Physiology paper describes it as a pharmacological peptide approach to tight junction regulation. It is indexed under tissue repair because its retrieved mechanism is epithelial barrier integrity rather than a shared receptor.
The clinical records are in coeliac disease: a 2012 American Journal of Gastroenterology randomised double-blind study during gluten challenge, a 2013 Alimentary Pharmacology and Therapeutics randomised placebo-controlled study, a 2015 Gastroenterology randomised controlled trial in patients with persistent symptoms despite a gluten-free diet, and a 2022 systematic review and meta-analysis of randomised controlled trials. A 2020 Frontiers in Chemistry paper and a 2021 International Journal of Molecular Sciences paper report in silico and derivative work against the SARS-CoV-2 main protease.
[3, 4, 5, 6, 7, 8, 9, 10, 11]Reported mechanism
A zonulin inhibitor reported in the retrieved records to regulate epithelial tight junctions and promote their assembly.
[3, 4, 12]Stated in the titles of the cited 2012 Peptides papers and the 2021 Current Medicinal Chemistry review.
Targets named in the cited records: epithelial tight junctions, zonulin pathway.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Larazotide appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- larazotide acetate
- AT-1001
- AT1001
Where this page sits
Research records
Cited research records for Larazotide, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
Class page: Tissue repair peptides. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Larazotide?
Larazotide, reported in the literature as larazotide acetate and by the code AT-1001, is an octapeptide studied as a regulator of epithelial tight junctions. Two 2012 Peptides papers report that it regulates tight junctions in vitro and in vivo and promotes tight junction assembly in epithelial cells, and a 2021 American Journal of Physiology paper describes it as a pharmacological peptide approach to tight junction regulation.
Which class is Larazotide indexed under?
Larazotide is indexed under Tissue repair peptides. This grouping covers peptides whose retrieved research literature is predominantly concerned with tissue repair endpoints in laboratory and animal models, rather than a single shared receptor.
What does the FDA application register show for Larazotide?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 9810532, Larazotide. PubChem, National Library of Medicine (2026). pubchem:9810532
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:larazotide
- Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides (2012). pmid:22401908
- Larazotide acetate promotes tight junction assembly in epithelial cells. Peptides (2012). pmid:22401910
- Larazotide acetate: a pharmacological peptide approach to tight junction regulation. American journal of physiology. Gastrointestinal and liver physiology (2021). pmid:33881350
- A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. The American journal of gastroenterology (2012). pmid:22825365
- Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Alimentary pharmacology & therapeutics (2013). pmid:23163616
- Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology (2015). pmid:25683116
- Larazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials. Clinics and research in hepatology and gastroenterology (2022). pmid:34339872
- <i>In silico</i> Analysis Revealed Potential Anti-SARS-CoV-2 Main Protease Activity by the Zonulin Inhibitor Larazotide Acetate. Frontiers in chemistry (2020). pmid:33520943
- Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation. International journal of molecular sciences (2021). pmid:34502335
- The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases. Current medicinal chemistry (2021). pmid:33397225
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.